Jump to content

Talk:Sophia Genetics

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Awards

[edit]

The awards section needs immediate clean-up. Any award that is primary sourced –e.g. cited to the awarding media outlet – is liable to be deleted. ☆ Bri (talk) 18:10, 17 June 2020 (UTC)[reply]

Deleted section. The other problem was that most if not all of these awards were lists of 50 or 100 awardees, which makes them even less appropriate for an encyclopedia. One award was also to the CEO as an individual, not to the company. All in all, this falls under PR style writing as documented at WP:Identifying PR. ☆ Bri (talk) 01:13, 18 June 2020 (UTC)[reply]

History edit request

[edit]

Hello Wikipedia editors, I'm Kelly, and I'm here on this Talk page as a Sophia Genetics employee to post my first edit request. I understand the importance of declaring a conflict of interest as an employee of the company, so I posted a detailed explanation of my COI on my user page here: User:Comms Kelly.

For this update, I've put together the most significant change I'm proposing: to absorb the Funding section of the article into the History section, keeping only the most essential bits of information. I totally understand why there is a Funding section within the article now, but since the company went public in 2021, offering a detailed breakdown of every minor round of funding from the 2010s seems like an over-explanation of now irrelevant information. Below, I'll list all the changes I'm proposing:

  • Updated the description of the Sophia DDM platform in the second paragraph of the History section, citing the following outlets to verify updated information: FierceBIotech, Medical Device Network, and TechCrunch. Also, I removed the TechTour citation from the section as the link is broken. Overall, I attempted to simplify the explanation of what the DDM platform does.
  • Removed the final sentence from the section's third paragraph, which read, "The algorithms were built bottom-up from raw FASTQ data." This read as way too science-specific for Wikipedia.
  • Removed the Funding section and ported over the funding round of Series E, Series F, and the paragraph about the company going public to the History section. I kept Series E because many high-quality citations were attached to this fundraising round.
  • Removed the following rounds of funding: Series A, Series B, Series C, and Series D.
  • In the paragraph regarding the acquisition of Interactive Biosoftware, added that IB was acquired for Alamut and added a small explanation of the product. I removed previous citations for this sentence (ICT Journal and La Tribune). I replaced them with citations from MobiHealthNews and GenomeWeb, which are better sources on the deal's specifics.
  • Removed the mention of Lara Hashimoto becoming Sophia's CBO because the citation link to her appointment at the company was broken. I attempted to find a replacement source but could not find anything of high quality also, coupled with the fact that she has since left the company, it made sense to remove it.
  • Removed the sentence about Sophia supporting 100 university hospitals in the US. I'll defer to editors, of course, but it did seem unbalanced to add just this one specific number.
  • Added the phrase "in response to the COVID-19 pandemic" in the sentence regarding Sophia's data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus.
  • I removed the mention of Sophia Genetics being listed on the Nasdaq towards the end of the article since this has already been addressed in an earlier section of the article.
  • Added a sentence about how there are 780 healthcare organizations within the Sophia DDM Network, cited to GEN.
  • Added a sentence about how, in 2022, Sophia Genetics hit one million genomic profiles, cited to Inside Precision Medicine.
  • Updated all access dates within each citation to show editors that each has been reviewed in this proposed update. I went through each of them and they all seem to be working and valuable.

Here is a drop-down box with the new History draft:

History draft

History

[edit]

Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as a start-up at École Polytechnique Fédérale de Lausanne (EPFL).[1] It began as a research tool for hospitals and federally regulated health care labs, and then expanded to biopharma institutions.[1]

In 2014, the company introduced the analytical software platform Sophia DDM (Data-Driven Medicine),[2] a cloud-based software-as-a-service platform that uses machine learning and AI algorithms to provide genomic insights to doctors and researchers from complex multimodal datasets.[3][4][5] Insights are shared across the platform's network, so as the user base scales, the AI becomes more accurate.[3][5] The platform is used for oncology and rare disease research.[5]

The company initially designed the platform to help hospitals with processing and storing large genomic data-sets, but research showed that the more pressing problem was data accuracy.[5] That then became the platform's primary focus. The startup worked with hospitals to benchmark DNA samples analyzed via their sequencing systems, and then trained algorithms of their own to perform the diagnosing process automatically and recognize relevant patterns in the genome data.[5]

To use the platform, DNA is extracted from a patient sample, enriched, and sequenced by an NGS machine.[5] Once this data has been digitized, it is loaded into the platform. The SOPHiA DDM Platform's AI algorithms then pull out unique genetic variants and pre-classifies data according to pathogenic predictions.[5] Doctors and researchers can then review the detected variants and take action – the SOPHiA DDM Platform in turn learns from those actions[5]

In 2017, Sophia Genetics was ranked as one of the 50 smartest companies in the world by the MIT Tech Review.[6]

In 2018, the company opened its first research and development center in France and acquired and genetic analytics software development company, Interactive Biosoftware, and Alamut, the company's clinical decision support software.[7][8] That same year, Sophia Genetics opened its U.S. headquarters in Boston, Massachusetts.[9] The company also received the Salus Partner Excellence in HealthTech Award in 2018.[10]

Sophia Genetics raised multiple rounds of funding before going public, including $77 million in January 2019 as part of a Series E round of funding, led by Generation Investment Management.[11][12][13]

In 2020, the company appointed Troy Cox, a former board of directors member, as its new chairman.[14] In August, in response to the COVID-19 pandemic, the company released a data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus.[15] The platform’s AI system was designed to conduct a full-genome analysis of the virus. It then combines that data with patient genetic information, and clinical data such as the results of lung and CT scans to discover abnormalities predictive of disease evolution.[15] Sophia Genetics also received the Best Overall Genomics Company in the 2020 MedTech Breakthrough Awards.[16]

In October 2020, as part of a Series F round of funding, the company raised $110 million led by aMoon, a health-tech and life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group.[17]

In 2021, Sophia Genetics went public, trading under the symbol SOPH on the Nasdaq.[18][19] The company raised $234 million in its IPO and was backed by J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse.[19]

Later in 2021, the company was named a Microsoft Partner of the Year finalist.[20] At the time, its platform was in use at more than 750 hospitals, laboratories, and biopharma institutions around the world and had analyzed over 770,000 genomic profiles worldwide.[3][4]

As of 2021, the company had 780 healthcare organizations within the Sophia DDM network.[21]

In April 2022, Sophia Genetics had analyzed over 1,000,000 genomic profiles.[22] Later in 2022, Sophia Genetics was named one of the 100 Best Places to Work in Boston by Built in Boston.[23]

Also in 2022, the firm began development of a new method for detecting extrachromosomal DNA through collaboration with startup firm Boundless Bio.[24]

References

  1. ^ a b "Genomics testing firm to triple Boston headcount after $110M round". Boston Business Journal. October 1, 2020. Retrieved October 14, 2024.
  2. ^ Park, Andrea (October 1, 2021). "Sophia Genetics teams up with OncoDNA to automate tumor profiling". Fierce Biotech. Retrieved October 14, 2024.
  3. ^ a b c "GE Healthcare and Sophia partner to develop AI-driven cancer solutions". Medical Device Network. July 7, 2021. Retrieved October 14, 2024.
  4. ^ a b "GE Healthcare announces three collaborations to advance cancer care". Med-Tech Innovation. 2021-12-09. Retrieved October 14, 2024.
  5. ^ a b c d e f g h Lomas, Natasha (September 13, 2017). "Balderton joins $30M Series D for big data biotech platform play, Sophia Genetics". TechCrunch. Retrieved October 14, 2024.
  6. ^ "50 Smartest Companies". MIT Technology Review. 2017. Retrieved October 14, 2024.
  7. ^ Versel, Neil (June 16, 2018). "Sophia Genetics Acquires Interactive Biosoftware". GenomeWeb. Retrieved October 14, 2024.
  8. ^ Comstock, Jonah (June 18, 2018). "Digital health briefs: Sophia Genetics acquires Biosoftware, Garmin improves sleep tracking, Yaoshibang gets $66M". MobiHealthNews. Retrieved October 14, 2024.
  9. ^ "Swiss company sets up US headquarters in Boston". Boston Globe. September 24, 2018. Retrieved October 14, 2024.
  10. ^ "RefleXion and Sofinnova Partners recognized with Salus Excellence Award". Imaging Technology News. September 25, 2020. Retrieved October 14, 2024.
  11. ^ Lomas, Natasha (January 4, 2019). "Sophia Genetics bags $77M Series E, with 850 hospitals signed up to its 'data-driven medicine'". TechCrunch. Retrieved October 14, 2024.
  12. ^ Wise, James (January 4, 2019). "Sophia Genetics announces new $77M funding round". Medium. Retrieved October 14, 2024.
  13. ^ O'Brien, Chris (4 January 2019). "Swiss startup Sophia Genetics raises $77 million to expand its AI diagnostic platform in the U.S." VentureBeat. Retrieved October 14, 2024.
  14. ^ Hale, Conor (February 21, 2020). "Sophia Genetics taps ex-Foundation Medicine CEO as chairman". FierceBiotech. Retrieved October 14, 2024.
  15. ^ a b Taylor, Phil (August 10, 2020). "Sophia Genetics launches AI tool to find COVID-19 'unknowns' -". pharmaphorum.com. Retrieved October 14, 2024.
  16. ^ "2020 Winners". MedTech Breakthrough. Retrieved October 14, 2024.
  17. ^ "Sophia Genetics raises $110M to fuel global data platform expansion". October 1, 2020. Retrieved October 14, 2024.
  18. ^ "Sophia Genetics Raises $234M in IPO, Eyes Additional Partnerships". GenomeWeb.
  19. ^ a b "Sophia Genetics goes public in $234M IPO, two other biotechs delay". Boston Business Journal. July 26, 2021. Retrieved October 14, 2024.
  20. ^ Bekker, Scott. "Social Impact a Focus of the 2021 Microsoft Partner of the Year Awards -". Redmond Channel Partner. Retrieved October 14, 2024.
  21. ^ Philippidis, Alex (August 9, 2021). "Creating a Clinical Crystal Ball: SOPHiA Genetics is Democratizing Data-Driven Medicine". GEN - Genetic Engineering and Biotechnology News. Retrieved November 18, 2024.
  22. ^ Albert, Helen (April 26, 2022). "SOPHiA Genetics Data-Driven Medicine Platform Hits One Million Genomic Profiles". Inside Precision Medicine. Retrieved November 15, 2024.
  23. ^ "100 Best Places To Work In Boston 2022 | Built In Boston". www.builtinboston.com. Retrieved October 14, 2024.
  24. ^ "Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection". GenomeWeb. September 21, 2022. Retrieved October 14, 2024.

I understand that this is a reasonably large edit request and that there will likely be feedback from editors. I'm certainly prepared to work together to get this draft to the best place possible within Wikipedia's guidelines. Thank you so much for taking the time to evaluate this draft, and I'll be around for responses as they come. Comms Kelly (talk) 21:04, 2 December 2024 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Sophia_Genetics&oldid=1260828281"